QUEBEC CITY,
June 6, 2013 /PRNewswire/ - Aeterna
Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"),
announced today that the previously disclosed purported class
action lawsuit filed against the Company and certain of its
officers (the "Defendants") by Faruqi & Faruqi LLP in the
United States District Court for the Southern District of
New York has been entirely
dismissed with prejudice and without leave to amend. No payment was
made by any of the Defendants to the plaintiff or his counsel in
connection with the lawsuit. The plaintiff has 30 days from the
docketing of the final judgment to file a notice of appeal, if he
determines to do so.
"We are extremely pleased that the Court recognized and
confirmed the Defendants' long-held view that the plaintiff's
claims were entirely without merit and granted in full and with
prejudice our motion to dismiss, producing the outcome that we had
expected all along", commented David
Dodd, President and Chief Executive Officer of Aeterna
Zentaris.
About Aeterna Zentaris Inc.
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.